• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

    11/5/24 10:55:09 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    SC 13G/A 1 ea0220038-13a1gponti4_nuve.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Nuvectis Pharma, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    67080T108

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 67080T108 13G Page 2 of 10 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax VI G.P. L.P.

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

     

     

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    288,8731

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    288,8731

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    288,8731

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.5%2

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    PN

     

    1.Consists of (a) 183,825 shares held by Pontifax (Israel) VI, L.P. and (b) 105,048 shares held by Pontifax (Cayman) VI, L.P. (collectively, the “Pontifax Entities”). Pontifax VI G.P. L.P. (“Pontifax VI GP”) is the general partner of each of the Pontifax Entities. Pontifax Management 4 G.P. (2015) Ltd. (“Pontifax Management”) is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.
      
    2.Based on 18,652,688 shares outstanding as of August 2, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on August 6, 2024.

     

     

     

     

    CUSIP No. 67080T108 13G Page 3 of 10 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax Management 4 G.P. (2015) Ltd.

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

     

     

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    288,8731

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    288,8731

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    288,8731

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.5%2

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    CO

     

    1.Consists of (a) 183,825 shares held by Pontifax (Israel) VI, L.P. and (b) 105,048 shares held by Pontifax (Cayman) VI, L.P. Pontifax VI GP is the general partner of each of the Pontifax Entities. Pontifax Management is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

    2.Based on 18,652,688 shares outstanding as of August 2, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on August 6, 2024.

     

     

     

     

    CUSIP No. 67080T108 13G Page 4 of 10 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Ran Nussbaum

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (c) ☐

    (d) ☐ 

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

     

     

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    288,8731

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    288,8731

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    288,8731

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.5%2

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

     

    1.Consists of (a) 183,825 shares held by Pontifax (Israel) VI, L.P. and (b) 105,048 shares held by Pontifax (Cayman) VI, L.P. Pontifax VI GP is the general partner of each of the Pontifax Entities. Pontifax Management is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

    2.Based on 18,652,688 shares outstanding as of August 2, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on August 6, 2024.

     

     

     

     

    CUSIP No. 67080T108 13G Page 5 of 10 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Tomer Kariv

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (e) ☐

    (f) ☐ 

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

     

     

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    288,8731

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    288,8731

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    288,8731

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.5%2

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

     

    1.Consists of (a) 183,825 shares held by Pontifax (Israel) VI, L.P. and (b) 105,048 shares held by Pontifax (Cayman) VI, L.P. Pontifax VI GP is the general partner of each of the Pontifax Entities. Pontifax Management is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

    2.Based on 18,652,688 shares outstanding as of August 2, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on August 6, 2024.

     

     

     

     

    CUSIP No. 67080T108 13G Page 6 of 10 Pages

     

    Introductory Note: This Schedule 13G is filed on behalf of Pontifax VI G.P. L.P., a limited partnership organized under the laws of the State of Israel, Pontifax Management 4 G.P. (2015) Ltd., an Israeli company, Ran Nussbaum and Tomer Kariv (the “Reporting Persons”), in respect of shares of common stock of Nuvectis Pharma, Inc.

     

    Item 1(a). Name of Issuer:

     

    Nuvectis Pharma, Inc.  

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    1 Bridge Plaza Suite 275

    Fort Lee, NJ 07024 

     

    Item 2(a). Name of Person Filing:

     

    This Statement is filed on behalf of Pontifax VI G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., Ran Nussbaum and Tomer Kariv.

     

    Item 2(b). Address of Principal Offices or, if None, Residence:

     

    The addresses of the Reporting Persons are:

    Pontifax VI G.P. L.P. - 14 Shenkar St. Herzliya, 46140, Israel

    Pontifax Management 4 G.P. (2015) Ltd. - 14 Shenkar St. Herzliya, 46140, Israel

    Ran Nussbaum - 14 Shenkar St. Herzliya, 46140, Israel

    Tomer Kariv - 14 Shenkar St. Herzliya, 46140, Israel

     

    Item 2(c). Citizenship:

     

    Pontifax VI G.P. L.P. is organized in the State of Israel, Pontifax Management 4 G.P. (2015) Ltd. is incorporated in the State of Israel, and Ran Nussbaum and Tomer Kariv are citizens of the State of Israel.

     

    Item 2(d). Title of Class of Securities: Common Stock, par value $0.00001 per share

      

    Item 2(e). CUSIP Number: 67080T108

     

    Item 3. If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a:  Not applicable.

      

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

    CUSIP No. 67080T108 13G Page 7 of 10 Pages

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                                    

      

    Item 4. Ownership.

     

      (a) Amount beneficially owned:

     

    288,8731

     

      (b) Percent of class:

     

    1.5%2

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: 0

     

      (ii) Shared power to vote or direct the vote: 288,8731

     

      (iii) Sole power to dispose or to direct the disposition of: 0

     

      (iv) Shared power to dispose or to direct the disposition of: 288,8731

     

    1.Consists of (a) 183,825 shares held by Pontifax (Israel) VI, L.P. and (b) 105,048 shares held by Pontifax (Cayman) VI, L.P. Pontifax VI GP is the general partner of each of the Pontifax Entities. Pontifax Management is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

    2.Based on 18,652,688 shares outstanding as of August 2, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on August 6, 2024.

     

     

     

     

    CUSIP No. 67080T108 13G Page 8 of 10 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person:

     

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person :

     

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group:

     

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10. Certification.

     

    Not applicable.

     

     

     

     

    CUSIP No. 67080T108 13G Page 9 of 10 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 5, 2024
     
    PONTIFAX VI G.P. L.P.  
         
    By: /s/ Pontifax Management 4 G.P. (2015) Ltd.  
    Name:   Pontifax Management 4 G.P. (2015) Ltd.  
    Title: General Partner  
         
    By: /s/ Ran Nussbaum  
    Name: Ran Nussbaum  
    Title: Director  
         
    PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.  
         
    By: /s/ Ran Nussbaum  
    Name: Ran Nussbaum  
    Title: Director  

     

    /s/ Ran Nussbaum  
    RAN NUSSBAUM
       
    /s/ Tomer Kariv  
    TOMER KARIV

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

    CUSIP No. 67080T108 13G Page 10 of 10 Pages

     

    EXHIBIT INDEX

     

    A. Joint Filing Agreement, dated as of February 4, 2024, by and among Pontifax VI G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., Ran Nussbaum and Tomer Kariv (Incorporated by reference from the Schedule 13G filed by the Reporting Persons with respect to the Issuer on February 4, 2024).

     

     

     

    Get the next $NVCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $171,664 worth of shares (21,167 units at $8.11) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/13/25 6:36:36 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Large owner Mosseri Marlio Charles bought $247,263 worth of shares (27,662 units at $8.94) (SEC Form 4)

      4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/12/25 9:25:24 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $235,647 worth of shares (27,411 units at $8.60) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/9/25 6:53:19 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

      Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Investor ConferenceDateMay 20th, 2025Time10:30 – 11:00 a.m. ETLinkNuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on

      5/16/25 4:35:00 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod

      5/6/25 8:00:11 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

      Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC Fort Lee, NJ, April 29, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innova

      4/29/25 4:25:00 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $171,664 worth of shares (21,167 units at $8.11) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/13/25 6:36:36 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Large owner Mosseri Marlio Charles bought $247,263 worth of shares (27,662 units at $8.94) (SEC Form 4)

      4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/12/25 9:25:24 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $235,647 worth of shares (27,411 units at $8.60) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/9/25 6:53:19 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      11/5/24 10:55:09 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/28/24 8:37:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nuvectis Pharma Inc.

      SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/6/24 8:47:33 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Nuvectis Pharma with a new price target

      Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

      4/2/25 8:05:05 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw initiated coverage on Nuvectis Pharma with a new price target

      Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

      3/17/25 7:40:44 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

      Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

      7/13/22 8:35:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    SEC Filings

    See more
    • Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:20:51 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Nuvectis Pharma Inc.

      424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:12:42 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Nuvectis Pharma Inc.

      10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/6/25 4:12:37 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care